Detailed Coverage

Broad and Deep Geographic Coverage

The EpicOncology™ platform provides detailed epidemiology data for the world’s leading cancer markets. You’ll find comprehensive cancer data sets for these 42 countries in the 2022 data release. 

Current and forecasted statistics, flow diagrams, and every data source logged and globally consistent…no other commercially available dataset offers the depth of coverage available in EpicOncology™.

EpicOncology™ Global Coverage

NORTH AMERICA CENTRAL AMERICA SOUTH AMERICA ASIA EUROPE MIDDLE EAST
United States Costa Rica Argentina Japan EU5 (DE, ES, FR, IT, UK) Egypt
Canada Dominican Republic Brazil China Mainland France Israel
Mexico Chile China Mainland Rural Germany Saudi Arabia
Panama Columbia China Mainland Urban Italy Turkey
Puerto Rico Ecuador China SAR* Spain
Peru Australia United Kingdom
South Korea Austria
Taiwan Belgium
India Denmark
Malaysia Finland
Singapore Netherlands
Thailand Norway
Poland
Portugal
Russia
Sweden
Switzerland

*Special Administrative Regions (Hong Kong and Macao)

EpicOncology™ Cancer Listing

Cancer and Subtype Coverage

EpicOncology™ includes detailed cancer data for more than 55 cancer sites and 110+ subtypes and biomarkers.  Every cancer site, subtype, and biomarker listed below, you’ll find in EpicOncology‘s data sets.

SOLID TUMORS

Cancers Subsets Biomarkers
All Sites1
Biliary Tract Gallbladder
Intrahepatic Bile Duct
Extrahepatic Bile Duct
Ampullary
Other Histologies
NTRK1 Gene Fusions
Bladder MSI-High
MSI-Stable
Other Urinary Renal Pelvis
Ureter
Other Histologies
MSI-High
MSI-Stable
Bone Osteosarcoma
Chondrosarcoma
Ewing’s Sarcoma
Other Histologies
NTRK1 Gene Fusions
Brain WHO Grade I
WHO Grade II
WHO Grade III (Anaplastic)
WHO Grade IV (Glioblastoma)
Secondary Glioblastoma
IDH1 Mutations
MSI-High
MSI-Stable
NTRK2 Gene Fusion
Breast HR-Positive, HER2-Positive
HR-Positive, HER2-Negative
HR-Negative, HER2-Positive
HR-Negative, HER2-Negative (TNBC)
PBRCA1 Positive
BRCA2 Positive
HER2 Positive
Hormone Positive
MSI-High
MSI-Stable
Cervical
Colorectal (Total) Colon
Rectal
Other BRAF Mutations
KRAS Mutation
KRAS Wild-Type
MSI-High
MSI-Stable
NRAS Mutation
Esophageal Adenocarcinoma (Non-GEJ)
Adenocarcinoma (GE Junction)
Squamous Cell
Other Histologies
MSI-High
MSI-Stable
Gastric Adenocarcinoma (Non-GEJ)
Adenocarcinoma (GE Junction)
HER2 Positive
MSI-High
MSI-Stable
Gastrointestinal Stromal Tumors
(GIST)
Gastric
Small Intestine
Other Sites
Head and Neck (Total) Squamous Cell
Non-Squamous Cell
Laryngeal
Oral Cavity
Oropharyngeal
Nasopharyngeal
Hypopharyngeal
Nasal Cavity & Sinuses
Squamous Cell
Non-Squamous Cell
Liver:
AJCC Staging
BCLC Staging
Child-Pugh Classification
Hepatocellular
Other Histologies
Lung, Non-Small Cell (NSCLC) Adenocarcinoma
Squamous Cell
Large Cell
Other Histologies
ALK Mutation
EGFR Mutation
KRAS Mutation
MSI-High
MSI-Stable
NTRK1 Gene Fusions
Lung, Small Cell (SCLC) Limited
Extensive
MSI-High
MSI-Stable
NTRK1 Gene Fusions
Melanoma BRAF V600E Mutation
Other BRAF Mutations
MSI-High
MSI-Stable
NRAS Mutation
Mesothelioma MSI-High
MSI-Stable
Ovarian High-Grade Serous
Low-Grade Serous
Other Histologies
BRCA1 Mutations
BRCA2 Mutations
Non-BRCA HRD Mutations
MSI-High
MSI Stable
Fallopian Tube High-Grade Serous
Low-Grade Serous
Other Histologies
BRCA1 Mutations
BRCA2 Mutations
Non-BRCA HRD Mutations
Pancreatic Adenocarcinoma
PNET
Other Histologies
MSI-High
MSI-Stable
Prostate Hormone Sensitive
Castrate Resistant
BRCA1 Mutations
BRCA2 Mutations
MSI-High
MSI-Stable
Renal Cell (Kidney) Clear Cell
Non-Clear Cell
MSI-High
MSI-Stable
Sarcoma, Soft Tissue Fibrohistiocytoma
Liposarcoma
Leiomyosarcoma
Rhabdomyosarcoma
Other Histologies
MSI-High
MSI-Stable
Thyroid Follicular
Papillary
Medullary
Anaplastic
Other Histologies
MSI-High
MSI-Stable
Endometrial Endometroid
Sarcoma
Other Histologies
MSI-High
MSI-Stable
Other Uterine Endometroid
Sarcoma
Other Histologies
MSI-High
MSI-Stable

1. All sites: includes some cancers that are NOT covered in EpicOncology™ (e.g., small intestine) but excludes non-melanoma skin cancers.

HEMATOLOGIC (HEME) MALIGNANCIES

Cancers Subsets Biomarkers
Leukemia: Acute Lymphocytic Leukemia (ALL) Ph-Positive
Ph-Negative
Leukemia: Acute Myeloid Leukemia (AML) Acute Myeloid Leukemia (AML)
Acute Promyelocytic Leukemia (APL)
Secondary AML (prior MDS-IPSS-R Very Low)
Secondary AML (prior MDS-IPSS-R Low)
Secondary AML (prior MDS-IPSS-R Intermediate)
Secondary AML (prior MDS-IPSS-R High)
Secondary AML (prior MDS-IPSS-R Very High)
Secondary AML (prior MPN)
CEBPA Mutation
IDH1 Mutations
FLT3-ITD Only
NPM1 & FLT3-ITD
NPM1 Mutation Only
MSI-Stable
Leukemia: Chronic Lymphocytic Leukemia (CLL)
Leukemia: Chronic Myelogenous Leukemia (CML) Chronic Phase
Accelerated Phase
Blast Crisis
Lymphoma, Hodgkin
Lymphoma, Non-Hodgkin (NHL) Follicular (Grade 1-2) Lymphoma
Follicular (Grade 3A) Lymphoma
Other Indolent B-cell Lymphoma
Follicular (Grade 3B) Lymphoma
Mantle Cell Lymphoma
Diffuse, Large B-Cell Lymphoma (DLBCL)
Other Aggressive B-cell Lymphoma
Cutaneous T-cell Lymphoma (CTCL)
Other Indolent T-cell Lymphoma
Peripheral T-cell Lymphoma (PTCL)
Other Aggressive T-cell Lymphoma
Multiple Myeloma Transplant Eligible
Transplant Ineligible
Myelodysplastic Syndromes (MDS) WHO Subsets
IPSS-R
Myeloproliferative Neoplasms (MPN) Polycythemia vera (PCV)
Essential Thrombocytosis (ET)
Myelofibrosis (MF)
JAK2

One Source for Global Cancer Epidemiology Data

How does EpicOncology™ present all this data to you? Through three integrated modules that help you query, map out, and analyze it.